IP Library Granted Patent US 9,474,563
Granted Patent B2
US 9,474,563 · App. 14/254,205 · Granted Oct 25, 2016

Methods for renal neuromodulation

Inventors: Denise Zarins (Saratoga, CA); Hanson Gifford, III (Woodside, CA); Mark Deem (Mountain View, CA); Douglas Sutton (Pacifica, CA); Howard R. Levin (Teaneck, NJ); Mark Gelfand (New York, NY)
Assignee: Medtronic Ardian Luxembourg S.a.r.l.
A61B18/12A61B18/04A61B18/1492A61N1/0551A61N1/36117A61N7/00A61B2018/0022A61B2018/00267A61B2018/00404A61B2018/00434A61B2018/00511A61B2018/00577A61B2018/00613A61B2018/00642A61B2018/00648A61B2018/00791A61B2018/00875A61N2007/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,474,563
App. No.
14/254,205
Granted
Oct 25, 2016
Kind
B2
Abstract

Methods and apparatus are provided for treating contrast nephropathy, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.

Claims (36)

1. A method for treating hypertension, the method comprising:

directing a neuromodulatory energy to a post-ganglionic renal nerve innervating a kidney of a human patient,

wherein directing the neuromodulatory energy to the post-ganglionic renal nerve comprises modulating the post-ganglionic renal nerve without completely physically severing the post-ganglionic renal nerve, and

wherein directing the neuromodulatory energy to the post-ganglionic renal nerve results in a therapeutically beneficial reduction in blood pressure of the patient.

2. The method of claim 1 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises modulating the renal nerve via an electric field.

3. The method of claim 2 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve via an electric field further comprises exposing the post-ganglionic renal nerve to a pulsed electric field.

4. The method of claim 2 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve via an electric field further comprises exposing the post-ganglionic renal nerve to a stimulation electric field.

5. The method of claim 1 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises at least partially denervating the kidney.

6. The method of claim 1 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises inducing an effect in the post-ganglionic renal nerve chosen from the group consisting of irreversible electroporation, electrofusion, necrosis, apoptosis, gene expression alteration, cytokine up-regulation alteration, and combinations thereof.

7. The method of claim 1 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises thermally modulating the post-ganglionic renal nerve.

8. The method of claim 1 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises modulating the post-ganglionic renal nerve with high frequency ultrasound.

9. The method of claim 1 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises modulating the post-ganglionic renal nerve via ultrasound energy.

10. A method for treating hypertension, the method comprising:

directing a neuromodulatory energy via an intravascularly delivered catheter to a post-ganglionic renal nerve innervating a kidney of a patient, wherein directing the neuromodulatory energy to the post-ganglionic renal nerve reduces neural signaling to and from the kidney of the patient; and

removing the catheter from the patient after modulating the post-ganglionic renal nerve,

wherein directing the neuromodulatory energy to the post-ganglionic renal nerve results in a therapeutically beneficial reduction in blood pressure of the patient.

11. The method of claim 10 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises modulating the post-ganglionic renal nerve via an electric field.

12. The method of claim 11 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve via an electric field further comprises exposing the post-ganglionic renal nerve to a pulsed electric field.

13. The method of claim 11 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve via an electric field further comprises exposing the post-ganglionic renal nerve to a stimulation electric field.

14. The method of claim 10 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises at least partially denervating the kidney.

15. The method of claim 10 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises inducing an effect in the post-ganglionic renal nerve chosen from the group consisting of irreversible electroporation, electrofusion, necrosis, apoptosis, gene expression alteration, cytokine up-regulation alteration, and combinations thereof.

16. The method of claim 10 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises thermally modulating the post-ganglionic renal nerve.

17. The method of claim 10 , wherein directing the neuromodulatory energy to the post-ganglionic renal nerve further comprises modulating the post-ganglionic renal nerve with high frequency ultrasound.

18. A method for treating hypertension, the method comprising:

directing one or more neuromodulatory agents or drugs to a post-ganglionic renal nerve innervating a kidney of a human patient,

wherein directing the one or more neuromodulatory agents or drugs to the post-ganglionic renal nerve comprises modulating the post-ganglionic renal nerve without completely physically severing the post-ganglionic renal nerve, and

wherein directing the one or more neuromodulatory agents or drugs to the post-ganglionic renal nerve results in a therapeutically beneficial reduction in blood pressure of the patient.

19. The method of claim 18 , wherein directing one or more neuromodulatory agents or drugs to the post-ganglionic renal nerve further comprises at least partially denervating the kidney.

20. The method of claim 18 , wherein directing one or more neuromodulatory agents or drugs to the post-ganglionic renal nerve further comprises inducing an effect in the post-ganglionic renal nerve chosen from the group consisting of irreversible electroporation, electrofusion, necrosis, apoptosis, gene expression alteration, cytokine up-regulation alteration, and combinations thereof.

21. A method for treating hypertension, the method comprising:

directing one or more neuromodulatory agents or drugs via an intravascularly delivered catheter to a post-ganglionic renal nerve innervating a kidney of a patient,

wherein directing the one or more neuromodulatory agents or drugs to the post-ganglionic renal nerve reduces neural signaling to and from the kidney of the patient; and

removing the catheter from the patient after directing the one or more neuromodulatory agents or drugs to the post-ganglionic renal nerve,

wherein directing the one or more neuromodulatory agents or drugs to the post-ganglionic renal nerve results in a therapeutically beneficial reduction in blood pressure of the patient.

22. The method of claim 21 , wherein directing one or more neuromodulatory agents or drugs to the post-ganglionic renal nerve further comprises at least partially denervating the kidney.

23. The method of claim 21 , wherein directing one or more neuromodulatory agents or drugs to the post-ganglionic renal nerve further comprises inducing an effect in the post-ganglionic renal nerve chosen from the group consisting of irreversible electroporation, electrofusion, necrosis, apoptosis, gene expression alteration, cytokine up-regulation alteration, and combinations thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2015
From: DEMARAIS, DENISE; GIFFORD, HANSON, III; DEEM, MARK; SUTTON, DOUGLAS
To: ARDIAN, INC.
Reel/Frame 035572/0083 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2015
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 035572/0311 →
CHANGE OF NAME Recorded May 6, 2015
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 035595/0728 →
Continuity (20)
Continuation 13898830 · May 21, 2013
Continuation 11368809 · Mar 6, 2006
Continuation In Part 10408665 · Apr 8, 2003
Continuation In Part 11133925 · May 20, 2005
Continuation 10900199 · Jul 28, 2004
Continuation In Part 10408665
Continuation In Part 11189563 · Jul 25, 2005
Continuation In Part 11129765 · May 13, 2005
Continuation In Part 10408665
Continuation In Part 11266993 · Nov 4, 2005
Continuation In Part 11363867 · Feb 27, 2006
Continuation In Part 11189563
Continuation In Part 11266993
Provisional Application 60442970 · Jan 29, 2003
Provisional Application 60415575 · Oct 3, 2002
Provisional Application 60370190 · Apr 8, 2002
Provisional Application 60616254 · Oct 5, 2004
Provisional Application 60624793 · Nov 2, 2004
Provisional Application 60813589 · Dec 29, 2005
Related Publication 20150080481A1 · Mar 19, 2015